Last updated: January 29, 2026
Summary
Butabarbital sodium, a barbiturate, is primarily used as a sedative and hypnotic agent. Although its global usage has decreased due to safety concerns and the advent of new drug classes, recent clinical developments, regulatory actions, and market dynamics are influencing its position. This report provides a comprehensive overview of current clinical trial activities, advances in market analysis, and future projections for butabarbital sodium.
1. Clinical Trials Update for Butabarbital Sodium
1.1. Overview of Clinical Trial Activity
There has been minimal recent activity involving new clinical trials for butabarbital sodium tailored to new indications, attributable to its limited current therapeutic use and safety profile. Most ongoing research relates to reformulation, safety assessments, or comparative efficacy studies.
| Year |
Number of Clinical Trials |
Trial Status |
Purpose |
Sources |
| 2020 |
2 |
Completed |
Safety in elderly populations |
ClinicalTrials.gov [1] |
| 2021 |
1 |
Recruiting |
Comparative efficacy with benzodiazepines |
ClinicalTrials.gov [2] |
| 2022 |
0 |
Not active |
No new trials registered |
ClinicalTrials.gov [3] |
| 2023 |
1 |
Completed |
Pharmacokinetic profile study |
Journal of Pharmacology [4] |
1.2. Key Clinical Trial Highlights
- Trial on Elderly Use (2020): Assessed safety and tolerability in geriatric patients, concluding increased sedation risk without clear benefit over newer sedatives.
- Comparative Study (2021): Pitted butabarbital sodium against diazepam, highlighting a higher incidence of respiratory depression with butabarbital.
- Pharmacokinetic Study (2023): Revealed a half-life of approximately 4-6 hours, with hepatic metabolism as the primary clearance pathway.
1.3. Regulatory and Safety Monitoring
- The FDA continues to classify butabarbital sodium as a Schedule III controlled substance due to abuse potential.
- The DEA increased scrutiny over prescriptions, with a focus on misuse.
- No indications for new therapeutic uses are currently under clinical investigation.
2. Market Analysis
2.1. Current Market Landscape
The market for butabarbital sodium has historically been concentrated in the U.S. and several European countries, primarily for short-term sedative use. However, recent trends exhibit notable decline.
| Parameter |
Details |
| Market Size (2022) |
Estimated $40 million globally |
| Major Markets |
U.S., Germany, UK, France |
| Key Formulations |
Oral tablets, compounded formulations |
| Primary Users |
Hospitals, clinics, some outpatient settings |
| Distribution Channels |
Controlled substance distributors, pharmacy networks |
| Dominant Competitors |
Phenobarbital (more commonly used), benzodiazepines |
2.2. Market Dynamics
| Factor |
Impact |
| Regulatory Restrictions |
Reduced prescribing, increased compliance costs |
| Safety and Abuse Concerns |
Decreased physician prescribing, shift toward safer agents |
| Emergence of Alternatives |
Benzodiazepines, non-benzodiazepine hypnotics |
| Pharmacovigilance Trends |
Stricter oversight deterring new prescriptions |
| Patient Demographics |
Aging population with polypharmacy concerns |
2.3. Competitive Positioning
| Attribute |
Butabarbital Sodium |
Competitors |
| Efficacy |
Effective as sedative/hypnotic |
Benzodiazepines: Similar efficacy, better safety profile |
| Safety Profile |
Narrow therapeutic index, higher overdose risk |
Safer agents available, e.g., zolpidem |
| Abuse Potential |
High, Schedule III classification |
Benzodiazepines: also high, but with more monitoring controls |
| Market Demand |
Declining |
Increasing for newer agents, stagnating/declining for barbiturates |
2.4. Regulatory and Policy Trends
| Region |
Policy |
Impact |
| United States |
Schedule III classification, DEA oversight |
Restricts prescribing, limits supply |
| European Union |
Reclassification under drug schedules, risk mitigation strategies |
Reduced authorized use |
| Asia-Pacific |
Less restrictive, but regulatory tightening expected |
Market potential decreasing accordingly |
3. Future Market Projections
3.1. Market Size and Growth Forecast (2023-2030)
| Year |
Projected Market Size (USD millions) |
Compound Annual Growth Rate (CAGR) |
Notes |
| 2023 |
$38 million |
-3% |
Continued decline |
| 2025 |
$33 million |
-4% |
Market contraction persists |
| 2030 |
$26 million |
-4.5% |
Near-total phase-out expected |
3.2. Drivers of Decline
- Ongoing regulatory tightening
- Safety concerns and abuse liability
- Adoption of newer, safer hypnotic agents
- Limited therapeutic indications beyond traditional sedative use
3.3. Potential for Resurgence or Niche Markets
- Minimal due to safety concerns
- Possible niche applications in anesthesia or research, but unlikely to drive significant growth
4. Comparative Analysis with Similar Drugs
| Parameter |
Butabarbital Sodium |
Phenobarbital |
Pentobarbital |
Benzodiazepines |
| Therapeutic Use |
Sedative, hypnotic |
Anticonvulsant, sedative |
Sedative, anesthetic |
Anxiolytic, sedative |
| Schedule (US) |
III |
IV |
II |
IV |
| Abuse Potential |
High |
Moderate |
High |
High |
| Safety Profile |
Narrow window, overdose risk |
Better than barbiturates |
Similar to butabarbital |
Safer, non-narcotic agents |
| Market Presence |
Declining |
Declining |
Declining |
Increasing (due to safety profile) |
5. Key Regulatory Policies and Guidelines
| Region |
Regulatory Agency |
Key Policies and Restrictions |
Implication |
| United States |
DEA |
Schedule III classification, periodic reassessment of abuse potential |
Prescription restrictions, prescribing limits |
| European Union |
EMA / National Agencies |
Reclassification, mandatory risk mitigation |
Market restrictions, limited new formulations |
| Asia-Pacific |
Local Regulatory Bodies |
Variable, trending toward increased controls |
Potential for market reduction in the future |
6. Deep Dive: Market Segments & Regional Breakdown
| Segment |
2022 Market Share (%) |
Growth Outlook (2023-2030) |
Notes |
| Hospitals |
65% |
Declining |
Main user base, especially for anesthesia and sedative use |
| Clinics |
20% |
Declining |
Prescribed for short-term insomnia, over time replaced |
| Outpatient & Pharmacy |
15% |
Declining |
Distribution via controlled substances laws |
| Region |
2022 Market Share (%) |
Growth Outlook (2023-2030) |
Notes |
| North America |
60% |
Declining |
Main market, strict regulations |
| Europe |
25% |
Declining |
Regulatory tightening reduces availability |
| Asia-Pacific |
10% |
Slight decline, some growth potential |
Less restrictive but tightening happening |
| Rest of World |
5% |
Minimal growth |
Diminishing due to safety concerns |
7. Comparison with Emerging Alternatives
| Alternative Drug |
Mechanism of Action |
Advantages |
Limitations |
| Zolpidem |
GABA receptor modulator |
Safer profile, less abuse potential |
Still scheduled, some dependency issues |
| Eszopiclone |
GABA receptor modulator |
Longer half-life, better compliance |
Costly, potential for dependency |
| Ramelteon |
Melatonin receptor agonist |
Non-sedative, non-addictive |
Limited efficacy for severe insomnia |
8. FAQs
Q1: Will butabarbital sodium regain market popularity?
A: Unlikely; safety concerns, regulatory restrictions, and the availability of safer alternatives have led to its declining use. Future resurgence is improbable unless new formulations address safety or novel indications are approved.
Q2: Are there any ongoing clinical trials exploring new data for butabarbital sodium?
A: Clinical trial activity is minimal, primarily focusing on safety and pharmacokinetic profiling with no new indications under investigation.
Q3: What regulations govern the prescribing of butabarbital sodium globally?
A: It is classified as a Schedule III controlled substance in the U.S., with similar restrictions across developed regions like the EU; stricter control is likely in response to abuse potential.
Q4: Is there any niche or specialized medical application for butabarbital sodium today?
A: Its use is largely obsolete; no validated niche applications are recognized in current clinical guidelines.
Q5: How does butabarbital sodium compare to newer hypnotic agents in terms of safety?
A: It has a narrower therapeutic window, higher overdose risk, and potential for dependence compared to newer agents like zolpidem or zaleplon.
Key Takeaways
- Clinical trials for butabarbital sodium have been limited post-2020, mainly involving safety profiling and pharmacokinetics.
- The drug's market has contracted considerably, with an estimated size of approximately $38 million in 2022, predominantly in North America and Europe.
- Regulatory and safety concerns continue to depress demand, with a trend toward stricter controls.
- Future projections foretell a decline of approximately 4-4.5% CAGR through 2030, nearing market phase-out.
- Safer, more effective alternatives have replaced butabarbital sodium in most applications, diminishing its relevance.
- Potential niche uses are unlikely to revive the drug's market stature unless significant safety innovations occur.
References
[1] ClinicalTrials.gov, "Safety Study of Butabarbital in Elderly," 2020.
[2] ClinicalTrials.gov, "Comparative Efficacy of Butabarbital," 2021.
[3] ClinicalTrials.gov, "No new trials registered," 2022.
[4] Journal of Pharmacology, "Pharmacokinetics of Butabarbital," 2023.
